Press Release / Health and Fitness / Think twice when you start a biosimilar project

Think twice when you start a biosimilar project

Use of monoclonal antibody drugs is a significant event in the history of medicine. In the last decade, the FDA has approved more than a dozen therapeutic monoclonal antibodies, targeting various types of disease such as leukemia, arthritis, and breast cancer. In 2013, the European Medicines Agency (EMA) approved the very first mAb biosimilar drug targeting rheumatoid arthritis.


At GenScript, we are dedicated to making products that accelerate drug discovery. Protein A CIP Resin is a special alkaline tolerant agarose media designed for antibody purification at the bioprocess level. With its dynamic binding capacity, extremely low ligand leakage, and enhanced alkali stability, Protein A CIP Resin is an ideal tool to reduce the cost of your monoclonal antibody research and development.